Treatment

Comparing exit strategies in natalizumab-responders at high risk for PML 7:33
Comparing exit strategies in natalizumab-responders at high risk for PML
Emanuele D'Amico • 30 Sep 2021
Improving stroke care in Brazil 3:15
Improving stroke care in Brazil
Sheila Martins • 21 Sep 2021
Key areas of research in multiple sclerosis 4:03
Key areas of research in multiple sclerosis
Mar Tintoré • 4 Oct 2021
New research looking into disease modifying treatments for atypical parkinsonism 2:32
New research looking into disease modifying treatments for atypical parkinsonism
Irene Litvan • 22 Sep 2021
Movement disorders: is searching for a cure hindering the development of symptomatic treatments? 2:16
Movement disorders: is searching for a cure hindering the development of symptomatic treatments?
Alfonso Fasano • 22 Sep 2021
Phase III SPARX3 trial of moderate- vs. high-intensity exercise to slow progression in PD 4:37
Phase III SPARX3 trial of moderate- vs. high-intensity exercise to slow progression in PD
Daniel Corcos • 23 Sep 2021
The future of neuromodulation strategies in movement disorders 1:43
The future of neuromodulation strategies in movement disorders
Andrea Kühn • 7 Sep 2021
The impact of LCIG on dyskinesia duration & severity in PD 4:19
The impact of LCIG on dyskinesia duration & severity in PD
Alfonso Fasano • 22 Sep 2021
Developments in DBS at MDS 2021 1:59
Developments in DBS at MDS 2021
Andrea Kühn • 7 Sep 2021
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS 3:26
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman • 15 Oct 2021
COVID-19 vaccination in patients with MS 7:22
COVID-19 vaccination in patients with MS
Maria Pia Sormani • 13 Oct 2021
Ublituximab: pending approval for relapsing MS 1:41
Ublituximab: pending approval for relapsing MS
Lawrence Steinman • 15 Oct 2021
Anti-C5 mAb eculizumab highly efficacious for the treatment of AQP4-positive NMOSD 3:11
Anti-C5 mAb eculizumab highly efficacious for the treatment of AQP4-positive NMOSD
Celia Oreja-Guevara • 14 Oct 2021
How does ublituximab compare to other anti-CD20 mAbs? 1:14
How does ublituximab compare to other anti-CD20 mAbs?
Lawrence Steinman • 15 Oct 2021
Upcoming treatments for Parkinson’s disease 1:10
Upcoming treatments for Parkinson’s disease
Zvezdan Pirtosek • 27 Sep 2021
Challenges in developing gene-based therapies for neurodegenerative & neuromuscular diseases 3:04
Challenges in developing gene-based therapies for neurodegenerative & neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
The content of VJNeurology is intended for healthcare professionals